Cantor Fitzgerald Estimates MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for MannKind in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share of $0.34 for the year. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.04 EPS for the quarter, meeting analysts’ consensus estimates of $0.04. The company had revenue of $70.08 million during the quarter, compared to analysts’ expectations of $77.27 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.

A number of other research analysts have also recently issued reports on MNKD. Wells Fargo & Company started coverage on shares of MannKind in a research report on Friday, December 20th. They set an “overweight” rating and a $9.00 price target for the company. StockNews.com lowered shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 7th. Finally, Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $7.00 to $10.00 in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $9.07.

MannKind Trading Down 3.6 %

Shares of MannKind stock opened at $5.95 on Thursday. MannKind has a 12 month low of $3.17 and a 12 month high of $7.63. The firm has a market capitalization of $1.64 billion, a P/E ratio of 85.00 and a beta of 1.29. The business has a fifty day simple moving average of $6.49 and a two-hundred day simple moving average of $6.26.

Hedge Funds Weigh In On MannKind

Hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its position in MannKind by 22.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,946 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 1,816 shares during the last quarter. National Bank of Canada FI increased its position in shares of MannKind by 14.8% during the 3rd quarter. National Bank of Canada FI now owns 21,553 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 2,783 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of MannKind by 8.1% in the 2nd quarter. AQR Capital Management LLC now owns 42,730 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 3,214 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of MannKind by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 101,435 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 3,374 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in MannKind by 3.0% during the third quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company’s stock valued at $1,047,000 after buying an additional 4,603 shares during the period. 49.55% of the stock is owned by institutional investors.

Insider Activity at MannKind

In related news, Director Steven B. Binder sold 67,539 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $6.76, for a total transaction of $456,563.64. Following the transaction, the director now owns 1,075,026 shares in the company, valued at $7,267,175.76. This represents a 5.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stuart A. Tross sold 55,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the completion of the sale, the insider now owns 967,191 shares in the company, valued at $7,099,181.94. This represents a 5.38 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is owned by corporate insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.